Interaction of 1,4-dihydropyridines with ion channels
Authors:
L. Veizerová; J. Světlík; V. Kettmann
Authors‘ workplace:
Univerzita Komenského, Farmaceutická fakulta, Katedra farmaceutickej analýzy a nukleárnej farmácie, Bratislava
Published in:
Čes. slov. Farm., 2008; 57, 58-62
Category:
Review Articles
Overview
The pharmacology of dihydropyridines in the cardiovascular system is widely known and the effects on L-type channels are well researched. There is far less information about the action of dihydropyridines on other classes of voltage-gated calcium channels. This article aims to bring more information about dihydropyridine derivates action on voltage-gated calcium channels or on Na⁺ a K⁺channels.
Key words:
Ca²⁺ channels – N-channel blockers – T-channel blockers – 1,4-dihydropyridines
Sources
1. Caterrall, W. A.: Pharmacol. Rev., 2005; 57, 411–425.
2. Josephson, I. R. et al.: Biophys. J., 2002; 83, 2575–2586.
3. Triggle, D. J.: Drug. Dev. Res., 2003; 58, 5–17.
4. Ertel, E. A. et al.: Neuron, 2000; 25, 533–535.
5. Hofmann, F. et al.: Rev. Biochem. Physiol., 1999; 139, 33–88.
6. Yu, F. H., Catterall, W. A.: Sci. STKE, 2004; 253, 15.
7. Tanaka, H., Shigenobu, K.: J. Pharmacol. Sci., 2005; 99, 214–220.
8. Hamid, J. et al.: Neuroscience, 2006; 143, 717–728.
9. Ono, K., Iijima, T.: J. Pharmacol. Sci., 2005; 99, 197–204.
10. Vitko, I. et al.: J. Neurosci., 2005; 25, 4844–4855.
11. Splawski, I. et al.: J. Biol. Chem., 2006; 281 (31), 22085–22091.
12. Yunker, A. M. R.: J. Bioenerg. Biomembr., 2003; 35, 6, 577–598.
13. Hagivara, N. et al.: J. Physiol., 1988; 395, 233–253.
14. Heady, T. N. et al.: Jpn. J. Pharmacol., 2001; 85, 339–350.
15. Masuda, Y. et al.: Cardiovasc. Drug Rev., 1994; 12, 123–135.
16. Masumiya, H. et al.: Eur. J. Pharmacol., 1998; 349, 351–357.
17. Furukawa, T. et al.: Br. J. Pharmacol., 2004; 143, 1050–1057.
18. Tanaka, H. et al.: J. Pharmacol. Sci., 2004; 96, 499–501.
19. Kumar, P. H. et al.: Mol. Pharmacol., 2002; 61, 649–658.
20. Triggle, D. J.: Mini Rev. Med. Chem, 2003; 3, 215–223.
21. Yamamoto, T. et al.: Bioorg. Med. Chem. Lett., 2006; 16, 798–802.
22. Mori, Y. et al.: Trends Cardiovasc. Med., 2002; 12, 270–275.
23. Saegusa, H. et al.: T. EMBO J., 2001; 20, 2349–2354.
24. Perez-Pinzon, M. A. et al.: J. Neurol. Sci., 1997; 153, 22–28.
25. Doering, C. J., Zamponi, G. W.: J. Bioenerg. Biomembr., 2003; 35 (6), 491–505.
26. Hu, L. Y. et al.: J. Med. Chem., 1999; 42, 4239–4249.
27. Roullet, J. B. et al.: J. Biol. Chem., 1999; 274, 25439–25446.
28. Murai, Y. et al.: Brain Res., 2000; 854, 6–10.
29. Murakami, M. et al.: Eur. J. Pharmacol., 2000; 419, 175–181.
30. Hu, W. Y. et al.: J. Cardiovas. Pharmacol., 2001; 38, 450–459.
31. Uneyama, H. et al.: Eur. J. Pharmacol., 1999; 373, 93–100.
32. Takahara, A. et al.: Hypertens. Res., 2003; 26, 741–752.
32a. Altier, Ch., Zamponi, G. W.: Trends Pharmacol. Sci., 2004; 29, 465–470.
33. Mintz, I. M. et al.: Nature, 1992; 355, 827–829.
34. Newcomb, N. et al.: Biochemistry, 1998; 37, 15353–15362.
35. Bourinet, E. et al.: Biophys. J., 2001; 81, 79–88.
36. Ellory, J. C. et al.: FEBS Letts., 1992; 296, 219–221.
37. Ellory, J. C. et al.: Brit. J. Pharmacol., 1994; 111, 903–905.
38. Klockner, U. et al.: Brit. J. Pharmacol., 1989; 97, 957–967.
39. Longman, S. D. et al.: Med. Res. Rev., 1992; 35, 2327–2340.
40. Li, J. H.: Cardiovascular Drug Reviews, 1997; 15, 220–231.
41. Yagupolskii, L. M. et al.: J. Med. Chem., 1999; 42, 5266–5271.
42. Kohlhardt, M. et al.: Naunyn–Schmied. Arch. Pharmacol., 1989; 340, 210–218.
43. Yatani, A. et al.: Circ. Res., 1985; 57, 868–875.
44. Haleen, S. J. et al.: J. Pharmacol. Exp. Therap., 1989; 250, 22–30.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2008 Issue 2
Most read in this issue
- Semisynthetic cellulose derivatives as the base of hydrophilic gel systems
- Lactobacilli and their probiotic properties
- Standard prescriptions for the formulation of medicinal preparations in pharmacies I. Suspensions for dermal administration
- Medicinal plants and diabetes mellitus